# Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients

> **NCT07728981** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Eye Hospital** · enrollment: 49 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

## Interventions

- **DRUG:** Aflibercept 8mg

## Key facts

- **NCT ID:** NCT07728981
- **Lead sponsor:** Tianjin Medical University Eye Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-25
- **Primary completion:** 2026-08-15
- **Final completion:** 2027-12-31
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07728981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07728981, "Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07728981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*